Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
Sabine Eichinger(Medical University of Vienna), Paul A. Kyrle(Karl Landsteiner Society), Verena Schönauer, Mirko Hirschl(Hanusch Hospital), Barbara Schneider(Altonaer Kinderkrankenhaus), Erich Minar, Christine Bialonczyk(Wilhelminen Hospital), Ansgar Weltermann, Peter Quehenberger
Cited by 159
Related Papers
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
|New England Journal of Medicine|2021|2.3k
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
|New England Journal of Medicine|1998|1.7k
High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism
|New England Journal of Medicine|2000|764
Deep vein thrombosis
|The Lancet|2005|620
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH
|Journal of Thrombosis and Haemostasis|2016|582